Compare Novavax Inc (NVAX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs TG Therapeutics Inc — how do they compare? Novavax Inc trades at $8.06 (market cap $1.30B), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: TG Therapeutics Inc is far larger — about 6.4× Novavax Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | TGTX | |
|---|---|---|
Market Cap | $1.30B | $8.26B |
Sector | Health | Health |
52-Week High | $11.19 | $59.06 |
52-Week Low | $6.22 | $26.39 |
Enterprise Value | $800.50M | $8.50B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
